Recently, in DLBCL patients, it has been demonstrated that mutations leading to defective glycosylation and trafficking of CD37 that, in consequence, lead to the lack of CD37 on the cell membrane are present only in the population with immune-privileged site-associated tumors. This evidence concerns the gene CD37 and diffuse large B-cell lymphoma.